Breast cancer, especially triple-negative (TNBC) — an active setting for personalized neoantigen vaccines plus immunotherapy.
Washington University School of Medicine is launching a Phase I trial for triple-negative breast cancer, evaluating a personalized cancer immunotherapeutic (PCI) strategy with or without a CD8-selective IL-2 mutein fusion protein. The addition of IL-2 modulation aims to enhance CD8+ T cell expansion and persistence during neoadjuvant chemoimmunotherapy.
Fred Hutchinson Cancer Center has launched a Phase I trial recruiting patients with stage IIIC-IV melanoma, metastatic breast cancer, or stage III-IV NSCLC. The study evaluates a personalized neo-antigen peptide vaccine combined with the Th1-polarizing adjuvant poly ICLC to induce polyclonal cytolytic T cell immunity.
The National Cancer Institute (NCI) is conducting a Phase II trial testing the addition of a personalized synthetic long peptide neoantigen vaccine to durvalumab, tremelimumab, and nab-paclitaxel in metastatic triple-negative breast cancer. This aims to determine if adding the vaccine improves outcomes over the standard chemo-immunotherapy backbone.
H. Lee Moffitt Cancer Center and Research Institute is recruiting for a Phase I pilot evaluating a personalized dendritic cell vaccine for high-risk triple-negative breast cancer (TNBC). The study utilizes whole exome sequencing of residual tumors post-neoadjuvant chemotherapy to assess safety, feasibility, and immunogenicity.
NEC Bio B.V. is recruiting for a Phase I/II trial of NECVAX-NEO1, a personalized neoantigen-targeting vaccine, in neoadjuvant triple-negative breast cancer. The study evaluates the vaccine in combination with standard-of-care anti-PD-1 therapy and chemotherapy, with potential post-surgical extension.